



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

Applicant: Robert J. Peach, et al.
Serial No.: 09/865,321
Filed: May 23, 2001
Docket: 30436.57USU1
Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 23, 2003.

By: 
Name: Tracy Cruick

55 South Lake Avenue, Suite 710
Pasadena, California 91101
June 23, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 173-194
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801


By: 
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA
Customer No. 26,941

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert J. Peach, et al.	Examiner:	Not Yet Known
Serial No.:	09/865,321	Group Art Unit:	1646
Filed:	May 23, 2001	Docket No.:	30436.57USU1
Title:	SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 23, 2003.


By: Tracy Truick

55 South Lake Avenue
Suite 710
Pasadena, California 91101
June 23, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b)(3))

This Supplemental Information Disclosure Statement should be considered because it is submitted before the mailing of a first Office Action on the merits according to 37 C.F.R. § 1.97 (b)(3). In accordance with 37 C.F.R. § 1.98(d), copies of Exhibits 173-194 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- European Publication No. EP 0 613 944 A2 published September 7, 1994. **(Exhibit 173)**
- European Publication No. EP 0 682 039 published November 15, 1995. **(Exhibit 174)**
- International Publication No. WO 98/56417 published December 17, 1998. **(Exhibit 175)**
- International Publication No. WO 95/34320 published December 21, 1995. **(Exhibit 176)**
- Sun, Hong et al., "Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody," *Transplantation*, 1997, 64:1838-56 **(Exhibit 177)**
- Souza, "Synergistic inhibition of established collagen induced arthritis (CIA) through dual inhibition of ICAM-1 and CD40L pathways," *Arthritis and Rheumatism*, 1999, page S60; abstract 64 **(Exhibit 178)**
- Blazar, Bruce R. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is A Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-Disparate Donor Grafts," *Blood*, 1995, 85:2607-18 **(Exhibit 179)**
- International Publication No. WO 01/92337 published December 6, 2001. **(Exhibit 180)**
- Najafian, et al., "CTLA4-Ig: a novel immunosuppressive agent," *Exp. Opin. Invest. Drugs*, 2000, 9:2147-2157. **(Exhibit 181)**
- U.S. Patent No. 5,770,197 issued June 23, 1998. **(Exhibit 182)**
- U.S. Patent No. 6,132,992 issued October 17, 2000. **(Exhibit 183)**
- U.S. Patent No. 6,090,914 issued July 18, 2000. **(Exhibit 184)**
- U.S. Patent No. 5,977,318 issued November 2, 1999. **(Exhibit 185)**
- U.S. Patent No. 5,885,579 issued March 23, 1999. **(Exhibit 186)**
- U.S. Patent No. 5,993,800 issued November 30, 1999. **(Exhibit 187)**
- U.S. Patent No. 5,916,560 issued June 29, 1999. **(Exhibit 188)**

- International Publication No. WO 01/90122 A2 published November 29, 2001. **(Exhibit 189)**
- International Publication No. WO 01/54732 A1 published August 2, 2001.
(Exhibit 190)
- International Publication No. WO 00/23115 published April 27, 2000. **(Exhibit 191)**
- International Publication No. WO 97/28267 published August 7, 1997. **(Exhibit 192)**
- International Publication No. WO 96/14865 published May 23, 1996. **(Exhibit 193)**
- Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," *Cell*, 1992, 71:1085-1088. **(Exhibit 194)**


No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the references are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Applicants invite the Patent Office to request additional information if necessary. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Robert J. Peach, et al.
Serial No. 09/865,321
Filed: May 23, 2001
Page 4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano
Registration No. 34,470
Roberta D. German
Registration No. 43,902
Patent Practitioners for Applicants
Mandel & Adriano
55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

JUN 2 5 2003

Sheet 1 of 2

FORM 1449*

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number

30436.57USU1

Application Number

09/865,321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

RECEIVED
JUN 27 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,770,197 (Exhibit 182)	June 23, 1998	Peter S. Linsley et al.			January 22, 1993
	6,132,992 (Exhibit 183)	October 17, 2000	Jeffrey A. Ledbetter et al.			October 5, 1995
	6,090,914 (Exhibit 184)	July 18, 2000	Peter S. Linsley et al.			July 18, 2000
	5,977,318 (Exhibit 185)	November 2, 1999	Peter S. Linsley et al.			June 7, 1995
	5,885,579 (Exhibit 186)	March 23, 1999	Peter S. Linsley et al.			July 8, 1997
	5,993,800 (Exhibit 187)	November 30, 1999	Peter S. Linsley et al.			June 6, 1995
	5,916,560 (Exhibit 188)	June 29, 1999	Christian P. Larsen et al.			March 20, 1997

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 613 944 A2 (Exhibit 173)	September 7, 1994	EPO				X
	EP 0 682 039 A1 (Exhibit 174)	November 15, 1995	EPO				X
	WO 98/56417 (Exhibit 175)	December 17, 1998	PCT				X
	WO 01/92337 (Exhibit 180)	December 6, 2001	PCT				X
	WO 95/34320 (Exhibit 176)	December 21, 1995	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Sun, Hong et al., "Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody," Transplantation, 1997, 64:1838-56 (Exhibit 177)
	Souza, "Synergistic inhibition of established collagen induced arthritis (CIA) through dual inhibition of ICAM-1 and CD40L pathways," Arthritis and Rheumatism, 1999, page S60; abstract 64 (Exhibit 178)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



(Use several sheets if necessary)

30436.30USI2

09/609,915

Peter S. Linsley et al.

July 3, 2000

1646

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/90122 A2 (Exhibit 189)	November 29, 2001	PCT			X	
	WO 01/54732 A1 (Exhibit 190)	August 2, 2001	PCT			X	
	WO 00/23115 (Exhibit 191)	April 27, 2000	PCT			X	
	WO 97/28267 (Exhibit 192)	August 7, 1997	PCT			X	
	WO 96/14865 (Exhibit 193)	May 23, 1996	PCT			X	

[illegible]

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.